Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne

被引:0
|
作者
Del Rosso, James [1 ,2 ,3 ]
Gold, Linda Stein [4 ]
Tyring, Stephen [5 ]
Zeichner, Joshua [6 ]
Callender, Valerie [7 ,8 ]
Draelos, Zoe [9 ]
Werschler, William [10 ]
Cook-Bolden, Fran [11 ]
Guenin, Eric [12 ]
机构
[1] JDR Dermatol Res Thomas Dermatol, Las Vegas, NV 89149 USA
[2] Adv Dermatol & Cosmet Surg, Maitland, FL 32751 USA
[3] Tour Univ Nevada, Henderson, NV 89014 USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[6] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[7] Callender Dermatol & Cosmet Ctr, Glenn Dale, MD USA
[8] Howard Univ, Coll Med, Washington, DC USA
[9] Dermatol Consulting Serv PLLC, High Point, NC USA
[10] Univ Washington, Sch Med, Seattle, WA USA
[11] Weill Cornell, Dept Dermatol, New York, NY USA
[12] Ortho Dermatol, Bridgewater, NJ USA
关键词
QUALITY-OF-LIFE; TOPICAL RETINOIDS; DOUBLE-BLIND; VULGARIS; MULTICENTER; ADAPALENE; SKIN;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: While topical retinoids are a mainstay of acne treatment, acne can manifest differently in various skin types. The objective of these post hoc analyses from two pooled phase 3 studies was to examine efficacy and safety of tazarotene 0.045% and quality of life improvements in self-identified Caucasian adults with moderate-to-severe acne. Methods: In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants aged >= 9 years with moderateto-severe acne were randomized (1:1) to tazarotene 0.045% lotion or vehicle lotion (N=1,614); a subset of adults (>= 18 years) who selfreported Caucasian (White) race (n=645) were examined. Coprimary endpoints were inflammatory/noninflammatory lesion counts and treatment (endpoint) success (>= 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 0 [clear] or 1 [almost clear]). Quality of life, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were also assessed. Results: At week 12, tazarotene lotion significantly reduced lesion counts by 60% (least-squares mean percent changes from baseline, tazarotene vs vehicle: inflammatory, -61.2% vs -51.1%; noninflammatory, -59.7% vs -49.3%; P<0.001, both). Significantly more participants achieved treatment success with tazarotene lotion versus vehicle (P<0.001). Numerical improvements in qualityof-life domains were observed from baseline to week 12. Most TEAEs were unrelated to treatment, and rates of moderate-to-severe erythema decreased from baseline to week 12 with tazarotene treatment. Conclusions: Tazarotene 0.045% lotion was efficacious and well tolerated over 12 weeks and led to quality-of-life improvements in Caucasian adults with moderate-to-severe acne. These results, along with those from patients with skin of color, demonstrate that once daily tazarotene 0.045% lotion is an effective and well-tolerated treatment option regardless of race or skin color.
引用
收藏
页码:1061 / 1069
页数:9
相关论文
共 50 条
  • [1] Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity
    Bhatia, Neal
    Weiss, Jonathan S.
    Sadick, Neil
    Cook-Bolden, Fran E.
    Tyring, Stephen K.
    Guenin, Eric
    Loncaric, Anya
    Harris, Susan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (07) : 727 - 734
  • [2] Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis
    Tanghetti, Emil A.
    Werschler, William Philip
    Lain, Edward
    Guenin, Eric
    Harris, Susan
    Loncaric, Anya
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (03) : 272 - 279
  • [3] Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex
    Green, Lawrence J.
    Del Rosso, James Q.
    Tanghetti, Emil A.
    Guenin, Eric
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (06) : 608 - 615
  • [4] Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males
    Cook-Bolden, Fran E.
    Gold, Michael H.
    Guenin, Eric
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (01) : 78 - 85
  • [5] New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis
    Eichenfield, Lawrence F.
    Tanghetti, Emil A.
    Guenin, Eric
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (06) : 602 - 610
  • [6] Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex
    Kircik, Leon H.
    Gold, Linda Stein
    Beer, Kenneth
    Tan, Jerry
    Baldwin, Hilary
    Guenin, Eric
    Kang, Robert
    Varughese, Johnson
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (08) : 777 - 783
  • [7] Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials
    Tanghetti, Emil A.
    Werschler, William P.
    Lain, Terry
    Guenin, Eric
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (01) : 70 - 77
  • [8] A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris
    Tanghetti, Emil A.
    Kircik, Leon H.
    Green, Lawrence J.
    Guenin, Eric
    Harris, Susan
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (06) : 542 - 548
  • [9] Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis
    Kircik, Leon H.
    Papp, Kim A.
    Gold, Linda Stein
    Harris, Susan
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 279 - 284
  • [10] Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
    Pariser, David M.
    Green, Lawrence J.
    Gold, Linda Stein
    Sugarman, Jeffrey L.
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 723 - 726